Vertex Pharmaceuticals Incorporated Appoints Ken Horton as Executive Vice President and Chief Legal Officer and Announces Retirement of Nancy Wysenski as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced two changes to its executive leadership team. Following a comprehensive search, Vertex has appointed Kenneth Horton to the role of Chief Legal Officer, where he will take on the additional title of Executive Vice President reporting to Vertex’s Chair, President and CEO Jeffrey Leiden, M.D., Ph.D. The company’s current Chief Legal Officer and Senior Vice President, Ty Howton, will work closely with Ken over the coming months to ensure a smooth transition. The company also announced today that its Chief Commercial Officer Nancy Wysenksi has decided to retire after joining Vertex in 2009 and building the company’s first commercial team to support the approval and launch of Vertex’s first medicines. A search for a new Chief Commercial Officer is currently ongoing.